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Purpose: Anterior chamber associated immune deviation (ACAID) is an antigen-specific form of peripheral immune
tolerance that is induced to exogenous antigens placed in the ocular anterior chamber, which leads to a suppression in
delayed-type hypersensitivity (DTH). Considerable work has been done on ACAID induction to major histocompatibility
(MHC) alloantigens. However, its role on cytotoxic T lymphocyte (CTL) activity is currently unknown.
Methods: C57BL/6 (H-2b) mice received an intracameral (IC) inoculation with BALB/c (H-2d) splenocytes. Splenic
CD4+ and CD8+ T cell populations were characterized by flow cytometry and proliferation assays during induction and
expression phases of ACAID. Percentages of CD4+CD25+FoxP3+ T regulatory cells (Treg) were also followed. Lastly,
CTL function was measured at various time points during ACAID expression, and Treg were added to identify potential
alterations in CTL function.
Results: CD4+ and CD8+ T cell percentages and proliferation increased in the spleen during ACAID induction but then
sharply decreased in response to an allospecific immunization. Expression of ACAID also exhibited a significant drop in
CTL function. However, while Treg expansion was observed, these cells did not directly mediate the CTL inhibition.
Conclusions: ACAID mediates an inhibition of CTL function against MHC alloantigens. Furthermore, we found that
ACAID induction leads to the expansion and proliferation of CD4+ and CD8+ T cells while ACAID expression is associated
with a diminishment in T cell percentages due to proliferation impairment. Lastly, Treg also expand during ACAID
induction. However, our data suggest that Treg do not directly inhibit CTL activity.
Anterior  chamber  associated  immune  deviation
(ACAID) is an antigen-specific form of peripheral immune
tolerance that is induced against exogenous antigens placed
in the ocular anterior chamber. Antigens inoculated into this
immune privileged space are processed regionally by F4/80+
antigen presenting cells (APC) [1] that favor induction of
tolerance  through  upregulated  TGF-β  production  with  a
concomitant  downregulation  of  CD40/CD40  ligand  and
interleukin (IL)-12 expression [2,3]. This APC population has
been  shown  to  migrate  directly  to  the  spleen  [4]  via
vascularized  structures  within  the  iridocorneal  angle  (i.e.,
trabecular meshwork) [5] and with the aid of other accessory
immune cells in the spleen, induces an antigen-specific state
of  immune  tolerance.  This  form  of  tolerance  is  mainly
characterized  by  a  suppression  of  delayed-type
hypersensitivity (DTH) reactions to the inoculated antigen
[6].
Also relevant in ACAID is the activity of cytotoxic T
lymphocytes (CTLs). These lymphocytes are CD8+ and are
known to be important in killing microbially infected host
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cells and the destruction of tumor cells. The influence of
ACAID expression on CTL function, however, is complex,
and our current understanding remains incomplete. While it
is known that intracameral inoculation with antigen-bearing
tumors in mice induces ACAID, Streilein and coworkers [6,
7] showed that CTL function in vitro nonetheless remains
intact. Interestingly, however, Xu and Kapp [8] and Mckenna
et al. [9] demonstrated that CTL function can be significantly
impaired following the induction of ACAID when soluble
antigens  are  inoculated  intracamerally.  Thus,  one  might
conclude that the nature of the antigen used to induce ACAID
impacts  the  manner  by  which  it  is  processed  and  the
subsequent effect on CTL.
CTL also plays a critical role in the immune rejection of
allogeneic  transplants,  albeit  not  against  major
histocompatibility  (MHC)  alloantigens  in  corneal
transplantation  [10-12].  Indeed,  corneal  allografts  induce
ACAID to MHC alloantigens borne by the corneal allograft
[13],  which  partially  explains  how  these  allografts  enjoy
higher survival rates relative to other forms of transplantation.
However, whether ACAID is responsible for downregulating
CTL function to MHC alloantigens is currently unknown, and
this may be potentially important in further understanding
increased corneal allograft survival. Moreover, further insight
into ACAID mechanisms that may inhibit CTL against MHC
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2435alloantigens  could  potentially  be  an  area  applicable  in
suppressing CTL in other forms of transplantation as well.
We have previously reported that intracameral delivery
of  MHC  allogeneic  splenocytes  (BALB/c)  into  C57BL/6
hosts induces ACAID [5]. In the present study, we have used
this model to directly examine the role of ACAID on CTL
function against allogeneic MHC targets. Furthermore, we
specifically  evaluated  the  possible  relevance  of
CD4+CD25+FoxP3+  regulatory  T  cells  (Treg)  during  the
induction of ACAID and whether this population might be
responsible for downregulating CTL function.
METHODS
Animals and anesthesia: Female C57BL/6 and BALB/c mice
six  to  eight  weeks  of  age  were  purchased  from  Jackson
Laboratories (Bar Harbor, Maine) and maintained under 12 h
light/12 h dark cycles. Mice were provided water and food ad
libitum.  All  procedures  were  performed  under  anesthesia,
which  included  an  intraperitoneal  injection  of  ketamine
(120 mg/kg whole bodyweight) and xylazine (20 mg/kg whole
bodyweight) suspended in 100 μl of sterile Hank’s Balanced
Salt  Solution  (HBSS).  Mice  were  euthanized  by  cervical
dislocation  following  anesthetization.  Throughout  these
studies,  mice  were  handled  according  to  guidelines
established by the ARVO Statement for the Use of Animals
in Ophthalmic and Vision Research and Public Health Policy
on Humane Care and Use of Laboratory Animals (US Public
Health  Review).  These  studies  were  approved  by  the
University of Florida’s IACUC.
Intracameral inoculation and subcutaneous immunizations:
The procedures for intracameral (IC) inoculation have been
described in detail elsewhere [5]. In brief, the cornea was
punctured  with  a  30  gauge  insulin  syringe  (BD  and  Co.,
Franklin  Lakes,  NJ)  and  approximately  2  μl  of  air  was
dispensed into the anterior chamber. An allogeneic splenocyte
suspension containing 1×106 cells per 2 µl in sterile HBSS
was then delivered into the anterior chamber. Microinjections
were  administered  with  a  pulled  10  μl  glass  micropipette
(Drummond Scientific Co., Broomall, PA) fitted into a sterile
infant feeding tube (No. 5 French; Cutter Laboratories, Inc.,
Berkeley, CA), which was attached to a 1 ml insulin syringe.
Immunizations consisted of allogeneic splenocytes in sterile
HBSS. Restraining the mice, immunizations were delivered
subcutaneously to the base of the tail using a sterile 30 gauge,
25 μl Hamilton syringe (Hamilton Co. Inc., Whittier, CA)
carefully avoiding the tail vein.
Delayed-type  hypersensitivity  assay:  This  assay  has  been
previously  described  elsewhere  [5].  In  brief,  γ-irradiated
(3000 R) splenocytes (106 cells per 10 µl) were loaded into a
30  gauge,  1  ml  insulin  syringe,  which  was  inserted
intradermally into the host ear pinnae. The needle was then
advanced  toward  the  outer  edge  of  the  pinnae,  and  cell
suspensions were slowly dispensed. Specific ear swelling was
measured with a micrometer (Mitutoyo, Aurora, IL) at the
location where the bolus was dispensed. These measurements
were administered before the challenge as a baseline, 24 h post
ear challenge, and 48 h post ear challenge. At each of these
time points, three individual measurements were taken per ear
and averaged. Peak DTH responses (either 24 h or 48 h) were
used to calculate specific ear swelling, which equals mean
peak measurements subtracted by the mean baseline.
Flow cytometry: Characterization of T cell populations was
performed on splenocytes from freshly sacrificed mice or on
cultured splenocytes. Cells were thoroughly washed in 0.5%
BSA and incubated with FC-receptor antibody (CD16/CD32)
in the dark at 4 °C for 15 min as per manufacturer’s instruction
(Becton  Dickinson  PharMingen).  Cells  were  then  double-
stained  with  FITC-conjugated  anti-CD4  or  PE-conjugated
anti-CD8 antibodies for 30 min in the dark at 4 °C according
to the manufacturer’s instruction (BD PharMingen). Aliquots
were  also  made  for  appropriate  isotype  controls.  For
intracellular staining, thoroughly washed cells first underwent
FC-receptor  blockade  and  cell  surface  staining  with  PE-
conjugated  anti-CD4  and  PECy7-conjugated  anti-CD25
antibodies (eBioscience, San Diego, CA) for 30 min in the
dark at 4 °C. Fixation and permeabilization was performed
overnight (eBioscience) followed by intracellular staining for
30 min with anti-Foxp3 antibody at 4 °C.
T cell proliferation: A small aliquot was taken from freshly
harvested  experimental  host  (C57BL/6)  splenocytes  to
enumerate  CD4+  and  CD8+  T  cell  percentages  before
allostimulation. The remainder was then stimulated in bulk
using BALB/c allosplenocytes (γ-irradiated at 3,000 R) at a
1:1 ratio to measure T cell proliferation. An upright T 25 flask
with 10 ml of Click’s medium (EHAA; Sigma- Aldrich, St.
Louis, MO) supplemented with10% fetal bovine serum was
used to culture 50.0×106 host splenocytes co-incubated with
an equal number of BALB/c stimulator cells at 37 °C for five
days. Flow cytometry was subsequently used to enumerate the
percentages of emanating CD4+ and CD8+ T cells. Ratios of
the respective T cell percentage after allostimulation over the
respective  percentage  enumerated  before  allostimulation
yielded the proliferation index.
Fluorolysis assay for CTL function and relevance of Treg:
The fluorolysis assay for CTL function in vitro has been
previously  described  [14].  Briefly,  harvested  splenocytes
from C57BL/6 were stimulated at a 1:1 ratio with BALB/c
allosplenocytes (γ-irradiated) and maintained for five days in
modified EHAA at 37 °C. Target cells were harvested from
allogeneic,  NOD/LtJ-eGFP+  (H-2Kd)  mice  and  stimulated
with LPS (5 μg/ml) for five days at 37 °C. Responder and
target cells were collected and enumerated via trypan blue
exclusion. Responder cells were re-plated in triplicate using a
96 well plate and co-cultured with target cells at ratios of 10:1,
2.5:1, and 1:1 (responder to target) for 4 h at 37 °C. After
incubation, harvested target cells were thoroughly washed and
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which yielded the target cell survival, a value that is inversely
proportional to CTL function.
We also assayed the relevance of Treg in CTL function.
Naïve T cells were stimulated in vitro and re-plated at a ratio
of 2.5 to 1 with eGFP+ target cells. Thus, 2.5×105 responders
Figure 1. ACAID is detectable up to 24 days following intracameral
inoculation. A: ACAID induction is typically tested approximately
14  days  post  intracameral  inoculation.  C57BL/6  mice  were
intracamerally (IC) inoculated with allogeneic BALB/c splenocytes
to induce ACAID. A subsequent immunization (IMM) with BALB/
c splenocytes was administered subcutaneously on day 7 to prime IC
inoculated mice. Naïve mice were similarly primed as a positive
control. Following the challenge with BALB/c splenocytes delivered
subcutaneously to the host ear pinnae (EAR), specific ear swelling
was then measured to assess DTH. Naïve mice were also challenged
as a negative control. B: ACAID was also detected 24 days post IC
inoculation. In other mice, IMM was administered on day 12, and
DTH was subsequently tested on day 24. Each group consisted of at
least  five  mice  or  more,  and  an  asterisk  indicates  statistical
significance (p<0.05) calculated via ANOVA.
with 1.0×105 targets were plated in a 96 well plate for a 4 h
CTL  assay.  Treg  were  magnetically  sorted  based  on
CD4+CD25+ markers from the spleens of ACAID-induced
mice and 0.35×105 were added, or cells not added as a control,
to the CTL assay. After incubation, harvested target cells were
thoroughly washed and were enumerated via flow cytometry
based on eGFP+ cells to yield the target cell survival.
Statistics: Data are presented as the standard error of the mean,
and statistical analyses included Student’s t-test or ANOVA
as indicated in respective figure captions. p values less than
0.05 were considered statistically significant.
RESULTS
ACAID is detectable out to 24 days following intracameral
inoculation: In the current study, C57BL/6 hosts (H-2b) were
inoculated  IC  with  spleen  cells  freshly  isolated  from
allogeneic  BALB/c  mice  (H-2d),  a  recipient-donor
combination  previously  shown  to  induce  ACAID  [5].
Following IC inoculation to induce ACAID, this response is
classically detected by first immunizing the recipient mice
seven days post IC inoculation with the inducing antigen.
Subsequently, approximately seven days after immunization,
inhibition of DTH can be observed to an antigen-specific
challenge  delivered  subcutaneously  to  the  recipient  ear
pinnae.  For  the  present  study,  we  elected  to  delay  these
intervals typically used to study ACAID to facilitate our study
of T cell immunity. Thus, immunization was given 12 days
after  IC  inoculation,  and  the  antigenic  challenge  was
subsequently delivered after another 12 days. As presented in
Figure 1, this alteration in the protocol did not affect the ability
of  ACAID  to  suppress  DTH  responses  as  this  form  of
tolerance was detectable up to 24 days post IC inoculation.
Characterizing responses by T cell subpopulations during the
induction and expression of ACAID: We first investigated
whether CD8+ T cells are expanding during the induction and/
or expression of ACAID to MHC alloantigens as this could
potentially confer the activation of a CTL response in the
current  model.  Moreover,  since  T  helper  cells  are  indeed
important in the activation/differentiation of CTL, CD4+ T
cells were also assessed. Flow cytometry was used to measure
CD4+ and CD8+ T cell percentages in host spleens, the critical
site for the activation of ACAID [4]. C57BL/6 mice were
inoculated IC with BALB/c allosplenocytes, and their spleens
were collected 4, 8, and 12 days post IC inoculation in addition
to 16, 20, and 24 days post IC inoculation. The initial three
time points (4, 8, and 12 days) allowed us to examine the
induction of ACAID. The latter time points (days 16, 20, and
24), which followed the delivery of an immunization, allowed
us to examine the expression of ACAID.
We  found  that  the  general  patterns  of  CD4+  T  cell
percentages (Figure 2A) are somewhat similar to those of
CD8+ T cells (Figure 2B) during the induction and expression
of  ACAID.  During  the  induction  of  ACAID,  there  is  a
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2437Figure 2. In vivo percentages of splenic
CD4+  and  CD8+  T  cells  and  their
proliferative responses in vitro during
the induction and expression of ACAID.
Induction  of  ACAID  to  MHC
alloantigens  is  associated  with  the
expansion of CD4+ (A) and CD8+ T (B)
cells  while  expression  of  ACAID  is
associated  with  a  reduction  of  T  cell
percentages.  C57BL/6  mice  were  IC
inoculated  with  allogeneic  BALB/c
splenocytes to examine the induction of
ACAID  and  was  followed  by
immunization   (IMM)  with  BALB/c
splenocytes to examine the expression
of ACAID. Splenocytes were harvested
at  the  indicated  time  points  (n=3  per
time point) for enumeration of T cell
percentages via flow cytometry. Naïve
spleens  were  similarly  assessed  and
presented  graphically  on  day  12.  An
asterisk indicates statistical significance
(p<0.05) calculated via Student’s t-test.
C: Induction of ACAID is associated
with  higher  proliferation  levels  while
expression of ACAID is associated with
lower proliferation levels. T cells were
harvested  from  hosts  (n=3  per  time
point) at the indicated time points and
stimulated in vitro to recall alloantigen
(BALB/c).
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2438substantial increase that takes place in both CD4+ (p<0.01)
and CD8+ T cells peaking on day 12 when comparing to
respective  splenic  T  cell  populations  in  naïve  mice.
Comparison of these respective peaks on day 12 to subsequent
time points following immunization then indicates a decrease
in CD4+ and CD8+ T cell populations. Statistically significant
decreases during ACAID expression occur in CD4+ T cells on
days 16 (p<0.05) and 24 (p<0.05; Figure 2A), and significant
decreases in CD8+ T cells occur on day 24 (p=0.044; Figure
2B).  Thus,  despite  the  considerably  delayed  delivery  of
immunization on day 12 post IC inoculation, only following
immunization  does  a  diminishment  in  the  splenic  T  cell
percentage occur. This suggests that it is the immunization of
IC inoculated mice that leads to the diminishment in splenic
T  cell  percentage  and  potentially  signifies  an  ACAID-
mediated  regulation  of  immune  responses  to  the
immunization.
We then assessed whether T cell proliferation plays a role
in  these  observed  alterations  of  CD4+  and  CD8+  T  cell
percentages during the induction and expression of ACAID.
Proliferative responses were therefore tested in vitro by using
recall alloantigen (BALB/c) stimulation of T cells harvested
at the indicated time points. T cells were left unfractionated
to maintain their proportionality in situ, which allows us to
recapitulate and evaluate their net effect on their proliferative
responses. Using this analysis, we found that the general trend
of  proliferation  for  both  T  cell  populations  is  somewhat
reflective of their percentage alterations observed in the spleen
(Figure 2C). The induction of ACAID is associated with peak
CD4+ (on day 8) and CD8+ T cell proliferation (on day 12)
while  the  expression  of  ACAID  is  associated  with  a
downregulation  of  proliferative  responses  in  these
populations, particularly on day 20, thus potentially indicating
ACAID-mediated  regulation  of  immune  responses  to  the
immunization.
The reduced levels of proliferation, especially in CD4+ T
cells, suggested a role for CD4+CD25+FoxP3+ T regulatory
cells (Treg) as these cells are well known for their ability to
suppress T cell proliferation [15]. To examine this possibility,
spleen   cells   from   naïve   mice  or  from  IC  inoculated
mice  on  days  4,  8,  and  12,  were  collected,  and  the
CD4+CD25+FoxP3+ T cell populations enumerated using flow
cytometry (Figure 3A). These time points allowed us to focus
on the induction of ACAID, particularly where the marked
suppression of CD4+ proliferation was observed around day
12. As presented in Figure 3B, IC inoculated mice exhibited
significantly increased levels of Treg cells on day 12 (p<0.05)
relative to those exhibited by naive mice.
The effect of ACAID induction on CTL and the relevance of
Treg function: The reduction of CD8+ T cell percentages in
the spleen in addition to the suppression of their proliferation
points to the possibility that important functional changes may
be taking place in effector CD8+ T cells during the expression
of  ACAID.  We  were  therefore  interested  in  testing  CTL
function following the immunization of IC inoculated mice.
This was tested by the fluorolysis assay [14] using recall in
vitro  allostimulated  (H-2d)  T  cells  co-cultured  with  GFP+
allospecific (H-2Kd) target cells at various responder:target
cell  ratios.  Flow  cytometry  was  subsequently  used  to
enumerate target cell survival, an assay in which values are
inversely proportional to CTL function. Baseline CTL activity
was established with in vitro stimulated T cells harvested from
naïve  mice  while  the  positive  control  employed  in  vitro
stimulated T cells from immunized mice harvested 4, 8, and
12 days post immunization. T cells were similarly harvested
from IC inoculated mice 4, 8, and 12 days post immunization.
As presented in Figure 4A, target cell survival in the
positive controls was significantly lower than baseline on day
4 post immunization, indicative of increased CTL activity
(p<0.01), while target cell survival at days 8 and 12 proved
statistically similar to baseline. Interestingly, following the
immunization of IC inoculated mice, a marked increase in
target cell survival (p<0.01) is exhibited on days 8 and 12
(Figure 4B) despite the fact that T cells harvested from day 4
post immunization exhibited activities lower than baseline.
These data show that ACAID suppresses the CTL response
against allo-MHC target cells. To then test whether ACAID-
induced Treg cells are directly involved in this suppression of
CTL activity, Treg from ACAID-induced mice were added to
the CTL cultures. As shown in Figure 4C, no significant effect
on  target  cell  survival  was  observed  with  the  addition  of
ACAID-induced Treg cells, suggesting that these cells do not
directly suppress the CTL activity in ACAID.
DISCUSSION
This  is  the  first  study  to  show  that  ACAID  mediates an
inhibition of CTL function against allogeneic MHC target
cells,  as  splenic  CD8+ T cells exhibited impaired responses
to subsequent immunization with alloantigens. Furthermore,
we  found  that  while  ACAID   induction   leads   to   the
expansion  and    proliferation  of   CD4+  and CD8+
  ACAID  expression  is  associated  with  a  reduction  in  T
cell     numbers    and     proliferation    potential    toward    the
immunizing  alloantigens.  Lastly,  we  observed    an
expansion of CD4+CD25+FoxP3+ Treg during the induction
of  ACAID.  However,  our  data  suggest  that  this  Treg
population probably does not directly inhibit CTL activity.
In  support  of  our  findings,  previous  studies  have
demonstrated that ACAID induced with soluble antigens can
lead to an inhibition of CTL function in vitro [8,9]. In contrast,
it  has  been  shown  that  ACAID  induced  with  exogenous
tumors may not inhibit in vitro CTL function [6,7,16,17].
These disparate responses in CTL activity associated with
ACAID are postulated to be a result of the nature of the antigen
(i.e.,  soluble  versus  cellular  antigen)  employed  to  induce
ACAID. Antigen-bearing tumor cells are capable of migrating
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T  cells,to the spleen following IC delivery [6], thereby circumventing
the processing by the ocular APC considered essential for the
induction of ACAID and directly priming the CTL response.
In  contrast,  soluble  alloantigens  inoculated  IC  would  be
processed by ocular APC, thereby skewing the response to
ACAID and subsequent tolerance.
In the current study, however, we found that allogeneic
spleen  cells,  which  include  allo-APC  capable  of  directly
presenting antigen via class I, induces a form of ACAID that
leads to reduced CTL function. Moreover, we have previously
shown that following IC inoculation, allogeneic spleen cells
can indeed exit the eye intact via the iridocorneal angle [5],
providing  the  opportunity  for  direct  presentation  by
inoculated allogeneic APC to the host. Thus, our current data
refute the notion that CTL inhibition in ACAID is exclusively
reserved for soluble antigens and further suggests that direct
presentation  by  IC  inoculated  cells  can  lead  to  CTL
impairment associated with ACAID induction. Whether this
event may be restricted to APC that become toleragenic with
exposure  to  high  levels  of  TGF-β  in  the  ocular  anterior
chamber [16] requires further investigation.
We also observed that while CD4+ and CD8+ T cells
undergo  expansion  in  the  spleen  during  the  induction  of
ACAID,  their  detectable  numbers  are  sharply  reduced  in
response  to  a  subsequent  immunization.  Because  this
Figure  3.  Intracameral  inoculation  leads  to  an  increase  in
CD4+CD25+FoxP3+ Treg. A: Flow cytometry was used to enumerate
Treg in the spleen. Triple-stained splenocytes for CD4+, CD25+, and
FoxP3+ were first gated on CD4+ (left) and then measured for CD25
and FoxP3 (center, right). B: ACAID induction leads to an increase
in Treg in the spleen. Spleens were harvested and enumerated for
Treg percentages in naïve mice or in IC inoculated mice on days 4,
8, and 12 (n=3 per time point). An asterisk indicates a statistically
significant increase (p<0.5) in percentage over the naïve control. The
statistical significance was calculated via Student’s t-test.
observation is consistent with decreased proliferation levels
in both CD4+ and CD8+ T cell populations, it seemed logical
that this decline was due to impairment in T cell proliferation
rather than simply the egress of T cells from the spleen. Not
surprisingly,  therefore,  that  we  observed  a  concomitant
expansion of CD4+CD25+FoxP3+ Treg cells during ACAID
induction, pointing to the possibility that these cells play an
important role in suppressing T cell proliferation in the spleen,
this is in line with both Keino et al. [18] and Zhang et al.
Figure 4. ACAID suppresses CTL function, and this suppression
does not appear to be directly mediated by CD4+CD25+FoxP3+ Treg.
Splenocytes were harvested on days 4, 8, and 12 (n=3 per time point)
post  immunization  from  positive  control  mice  (A)  or  ACAID
expressing mice (B). Following their alloantigen stimulation in vitro,
responder cells were plated with allospecific eGFP+ target cells at
ratios of 2.5, 5, and 10 to 1 (responder to target) in triplicate wells.
Baseline activity was obtained with in vitro allostimulated naïve
splenocytes.  Flow  cytometry  was  used  to  enumerate  target  cell
survival, values that are inversely proportional to CTL function. An
asterisk indicates statistical significance as calculated by ANOVA.
C: ACAID-induced Treg do not directly suppress CTL function.
Baseline CTL cultures were incubated at a 2.5:1 ratio and splenic
Treg magnetically sorted from ACAID-induced mice were added to
CTL  assays.  No  statistical  (NS)  difference  was  observed  as
calculated via Student’s t-test.
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rather than natural Treg in mediating ACAID, as previously
described by Keino et al. [18].
However, our results suggest that while direct regulation
of CTL function in vitro by other T cells (i.e., δγ T cells) has
been reported [8], CD4+CD25+FoxP3+ Treg cells induced by
ACAID do not directly suppress CTL function. It is more
likely that these ACAID-induced Treg cells suppress CTL by
an  indirect  means,  e.g.,  by  inhibiting  helper  CD4+  T  cell
function,  which  is  important  in  promoting  CD8+  T  cell
differentiation  and  effector  activity.  Although  this  latter
hypothesis is attractive, it will be necessary to prove such
cellular interactions exist in ACAID-induced suppression of
CTL activity. It is also important to point out that CD8+ Treg,
known to suppress the expression of DTH in ACAID [20],
were also presumably generated in the current study. Future
work will be required to define their potential role, if any, in
the suppression of CTL responses observed in this study.
In summary, we report that IC induction of ACAID is
detectable up to at least 24 days, and this is associated with
the suppression of CTL function to MHC allogeneic targets.
Furthermore,  these  data  suggest  that  suppression  of  CTL
activity is not directly mediated by CD4+CD25+FoxP3+ Treg
generated during the induction of ACAID. Understanding this
aspect is important as it raises questions as to whether these
data possibly explain why CTL activity is minimal in corneal
allograft rejection [10-12] as these grafts indeed lead to the
induction of ACAID [13]. Lastly, the current model may offer
further  insight  into  ACAID  mechanisms  that  inhibit  CTL
against  MHC  alloantigens,  an  area  that  is  potentially
applicable  in  suppressing  CTL  in  other  forms  of
transplantation as well.
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